$CELC
Celcuity Inc Stock $celc

$celc Overview Financials Valuation SEC Filings Company Website

2021 Q3 Form 10-Q Financial Statement

#000165495421008769 Filed on August 11, 2021

Income Statement

Concept	2021 Q3	2021 Q2	2020 Q4
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$639.3K	$573.4K	$440.0K
YoY Change	22.94%	27.41%	10.0%
% of Gross Profit
Research & Development	$4.961M	$13.07M	$2.110M
YoY Change	152.75%	640.0%	40.67%
% of Gross Profit
Depreciation & Amortization	$63.61K	$76.60K	$100.0K
YoY Change	-36.39%	-23.4%	11.11%
% of Gross Profit
Operating Expenses	$5.600M	$13.64M	$2.550M
YoY Change	125.79%	516.25%	34.21%
Operating Profit	-$5.600M	-$13.64M
YoY Change	125.79%	516.25%
Interest Expense	-$427.5K	$391.2K	$0.00
YoY Change	-1526742.86%	1261793.55%	-100.0%
% of Operating Profit
Other Income/Expense, Net	-$427.5K	-$389.4K
YoY Change	-7499.34%	-3357.9%
Pretax Income	-$6.027M	-$14.03M	-$2.550M
YoY Change	143.59%	537.28%	40.88%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$6.027M	-$14.03M	-$2.550M
YoY Change	143.59%	537.28%	40.88%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.41	-$1.11
Diluted Earnings Per Share	-$405.1K	-$1.113M	-$248.1K
COMMON SHARES
Basic Shares Outstanding	14.90M shares	12.61M shares	10.30M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2021 Q3	2021 Q2	2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$90.37M	$41.64M	$11.64M
YoY Change	559.61%	169.85%	-37.89%
Cash & Equivalents	$90.37M	$41.64M	$11.64M
Short-Term Investments
Other Short-Term Assets	$459.4K	$422.9K	$340.0K
YoY Change	282.8%	69.14%	6.25%
Inventory
Prepaid Expenses		$279.5K	$317.0K
Receivables
Other Receivables		$190.0K	$190.0K
Total Short-Term Assets	$91.18M	$42.25M	$12.17M
YoY Change	550.75%	166.07%	-36.8%
LONG-TERM ASSETS
Property, Plant & Equipment	$655.1K	$415.1K	$558.9K
YoY Change	4.61%	-49.99%	-32.95%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$655.1K	$557.8K	$789.8K
YoY Change	-27.37%	-31.97%	-23.35%
TOTAL ASSETS
Total Short-Term Assets	$91.18M	$42.25M	$12.17M
Total Long-Term Assets	$655.1K	$557.8K	$789.8K
Total Assets	$91.84M	$42.81M	$12.96M
YoY Change	515.78%	156.34%	-36.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.746M	$647.2K	$217.4K
YoY Change	2000.84%	708.97%	52.25%
Accrued Expenses	$1.070M	$729.7K	$774.6K
YoY Change	41.41%	-1.4%	32.57%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$5.830K	$0.00
YoY Change
Long-Term Debt Due	$5.840K	$5.830K	$10.00K
YoY Change	-41.6%	-41.7%	0.0%
Total Short-Term Liabilities	$2.823M	$1.536M	$1.185M
YoY Change	172.66%	85.1%	30.06%
LONG-TERM LIABILITIES
Long-Term Debt	$14.43M	$14.24M	$10.00K
YoY Change	144217.3%	142284.5%	0.0%
Other Long-Term Liabilities	$108.9K	$0.00	$60.00K
YoY Change	-0.98%		0.0%
Total Long-Term Liabilities	$14.54M	$14.24M	$70.00K
YoY Change	12017.21%	142284.5%	0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.823M	$1.536M	$1.185M
Total Long-Term Liabilities	$14.54M	$14.24M	$70.00K
Total Liabilities	$17.36M	$15.77M	$1.254M
YoY Change	1407.23%	1777.95%	27.59%
SHAREHOLDERS EQUITY
Retained Earnings			-$26.32M
YoY Change			56.24%
Common Stock			$10.30K
YoY Change			0.45%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$74.47M	$27.03M	$11.70M
YoY Change
Total Liabilities & Shareholders Equity	$91.84M	$42.81M	$12.96M
YoY Change	515.78%	156.34%	-36.11%

Cashflow Statement

Concept	2021 Q3	2021 Q2	2020 Q4
OPERATING ACTIVITIES
Net Income	-$6.027M	-$14.03M	-$2.550M
YoY Change	143.59%	537.28%	40.88%
Depreciation, Depletion And Amortization	$63.61K	$76.60K	$100.0K
YoY Change	-36.39%	-23.4%	11.11%
Cash From Operating Activities	-$4.049M	-$7.619M	-$2.110M
YoY Change	145.38%	388.41%	23.39%
INVESTING ACTIVITIES
Capital Expenditures	-$14.06K	-$27.90K	-$10.00K
YoY Change	40.6%	39.5%	-66.67%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$500.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$14.06K	-$27.40K	-$10.00K
YoY Change	40.6%	37.0%	-100.24%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	52.79M	14.35M	60.00K
YoY Change	-75515.63%	9464.91%	100.0%
NET CHANGE
Cash From Operating Activities	-4.049M	-7.619M	-2.110M
Cash From Investing Activities	-14.06K	-27.40K	-10.00K
Cash From Financing Activities	52.79M	14.35M	60.00K
Net Change In Cash	48.73M	6.701M	-2.060M
YoY Change	-2916.66%	-568.58%	-183.74%
FREE CASH FLOW
Cash From Operating Activities	-$4.049M	-$7.619M	-$2.110M
Capital Expenditures	-$14.06K	-$27.90K	-$10.00K
Free Cash Flow	-$4.035M	-$7.591M	-$2.100M
YoY Change	146.01%	392.94%	25.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	14904898	shares
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41638623	USD
CY2021Q2	us-gaap	Deposits Assets Current DepositsAssetsCurrent	22009	USD
CY2021Q2	us-gaap	Deferred Costs Current DeferredCostsCurrent	121307	USD
CY2021Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	190000	USD
CY2021Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	279544	USD
CY2021Q2	us-gaap	Assets Current AssetsCurrent	42251483	USD
CY2021Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	415080	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142766	USD
CY2021Q2	us-gaap	Assets Assets	42809329	USD
CY2021Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	647172	USD
CY2021Q2	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5830	USD
CY2020Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	5810	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153684	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	187518	USD
CY2021Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	729672	USD
CY2021Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1536358	USD
CY2021Q2	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	5379	USD
CY2020Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	8299	USD
CY2021Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60861	USD
CY2021Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	14233068	USD
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	0	USD
CY2020Q4	us-gaap	Liabilities Liabilities	1254477	USD
CY2021Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	2500000	shares
CY2021Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	25000000	shares
CY2021Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	12654898	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10299822	shares
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	10300	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	38013551	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26321581	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11702270	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12956747	USD
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13070108	USD
CY2020Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1766227	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15306451	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3613641	USD
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	573360	USD
CY2020Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	447714	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1128787	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	911113	USD
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	13643468	USD
CY2020Q2	us-gaap	Operating Expenses OperatingExpenses	2213941	USD
	us-gaap	Operating Expenses OperatingExpenses	16435238	USD
	us-gaap	Operating Expenses OperatingExpenses	4524754	USD
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-13643468	USD
CY2020Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2213941	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16435238	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4524754	USD
CY2021Q2	us-gaap	Interest Expense InterestExpense	391187	USD
CY2020Q2	us-gaap	Interest Expense InterestExpense	31	USD
	us-gaap	Interest Expense InterestExpense	391210	USD
	us-gaap	Interest Expense InterestExpense	64	USD
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	1803	USD
CY2020Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	11983	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2191	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	75834	USD
CY2021Q2	celc	Loss On Sale Of Fixed Assets LossOnSaleOfFixedAssets	0	USD
CY2020Q2	celc	Loss On Sale Of Fixed Assets LossOnSaleOfFixedAssets	0	USD
	celc	Loss On Sale Of Fixed Assets LossOnSaleOfFixedAssets	263	USD
	celc	Loss On Sale Of Fixed Assets LossOnSaleOfFixedAssets	0	USD
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-389384	USD
CY2020Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	11952	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-389282	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	75770	USD
CY2021Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-14032852	USD
CY2020Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2201989	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-16824520	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4448984	USD
CY2021Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-14032852	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2201989	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16824520	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4448984	USD
CY2021Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.11
CY2020Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.21
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.42
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.43
CY2021Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12610917	shares
CY2020Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10260234	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11845758	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	10257111	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	11702270	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	449098	USD
CY2021Q1	celc	Exercise Of Common Stock Warrants Amount ExerciseOfCommonStockWarrantsAmount	11257	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	0	USD
CY2021Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	25768493	USD
CY2021Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	38962	USD
CY2021Q1	celc	Issuance Costs Associated With Atm Offering IssuanceCostsAssociatedWithAtmOffering	-3868	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-2791668	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	35174544	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	540317	USD
CY2021Q2	celc	Employee Stock Purchases Amount EmployeeStockPurchasesAmount	25817	USD
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	36859	USD
CY2021Q2	celc	Warrant Issued Note Payable WarrantIssuedNotePayable	289839	USD
CY2021Q2	celc	Issuance Of Common Stock Licensing Agreement Amount IssuanceOfCommonStockLicensingAgreementAmount	5000000	USD
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-14032852	USD
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	27034524	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	19297571	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Share Based Compensation Gross StockIssuedDuringPeriodValueShareBasedCompensationGross	464649	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-2246995	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	17515225	USD
CY2020Q2	celc	Employee Stock Purchases Amount EmployeeStockPurchasesAmount	23897	USD
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	154142	USD
CY2020Q2	celc	Issuance Costs Associated With Atm Offering IssuanceCostsAssociatedWithAtmOffering	-52110	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-2201989	USD
CY2020Q2	us-gaap	Stockholders Equity StockholdersEquity	15862358	USD
	us-gaap	Net Income Loss NetIncomeLoss	-16824520	USD
	us-gaap	Net Income Loss NetIncomeLoss	-4448984	USD
	us-gaap	Depreciation Depreciation	176597	USD
	us-gaap	Depreciation Depreciation	191134	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	989415	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	887842	USD
	celc	Issuance Of Common Stock Licensing Agreement IssuanceOfCommonStockLicensingAgreement	5000000	USD
	celc	Issuance Of Common Stock Licensing Agreement IssuanceOfCommonStockLicensingAgreement	0	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	81571	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	0	USD
	celc	Pik Interest PikInterest	93397	USD
	celc	Pik Interest PikInterest	0	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	263	USD
	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	37496	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	41952	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	438018	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-59025	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-124940	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	26189	USD
	celc	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	-6550	USD
	celc	Increase Decrease In Non Cash Operating Lease Expense IncreaseDecreaseInNonCashOperatingLeaseExpense	-28754	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-10139253	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3389646	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	57897	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	66589	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	500	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-57397	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-66589	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	11257	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	36859	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	USD
	celc	Proceeds From Employee Stock Purchases ProceedsFromEmployeeStockPurchases	25817	USD
	celc	Proceeds From Employee Stock Purchases ProceedsFromEmployeeStockPurchases	23897	USD
	celc	Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts	25768493	USD
	celc	Proceeds From Follow On Offering Net Of Underwriting Discounts And Offering Costs ProceedsFromFollowOnOfferingNetOfUnderwritingDiscountsAndOfferingCosts	0	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	14347939	USD
	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
	celc	Gross Proceeds From An Atm Offering GrossProceedsFromAnAtmOffering	38962	USD
	celc	Gross Proceeds From An Atm Offering GrossProceedsFromAnAtmOffering	154142	USD
	celc	Payments For Registration Statement Costs PaymentsForRegistrationStatementCosts	29065	USD
	celc	Payments For Registration Statement Costs PaymentsForRegistrationStatementCosts	23367	USD
	celc	Payments For Finance Leases PaymentsForFinanceLeases	2900	USD
	celc	Payments For Finance Leases PaymentsForFinanceLeases	2880	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	40197362	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	151792	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	30000712	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-3304443	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11637911	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18735002	USD
CY2021Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41638623	USD
CY2020Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15430559	USD
	celc	Offering And Registration Statement Costs Included In Accounts Payable And Accrued Expenses OfferingAndRegistrationStatementCostsIncludedInAccountsPayableAndAccruedExpenses	96111	USD
	celc	Offering And Registration Statement Costs Included In Accounts Payable And Accrued Expenses OfferingAndRegistrationStatementCostsIncludedInAccountsPayableAndAccruedExpenses	0	USD
	celc	Issuance Of Common Stock Warrants And Final Fee Recognized As Discount To Note Payable IssuanceOfCommonStockWarrantsAndFinalFeeRecognizedAsDiscountToNotePayable	964839	USD
	celc	Issuance Of Common Stock Warrants And Final Fee Recognized As Discount To Note Payable IssuanceOfCommonStockWarrantsAndFinalFeeRecognizedAsDiscountToNotePayable	0	USD
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">Management uses estimates and assumptions in preparing these unaudited condensed financial statements in accordance with U.S. GAAP. Those estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities, and the reported revenues and expenses. Actual results could differ from those estimates and the difference could be material. Significant items subject to such estimates and assumptions include the valuation of stock-based compensation and prepaid or accrued clinical trial costs.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Company is subject to risks common to companies in the development stage including, but not limited to, dependency on the clinical and commercial success of its diagnostic tests, ability to obtain regulatory approval of its diagnostic tests, the clinical and commercial success of its initial drug product, gedatolisib, the need for substantial additional financing to achieve its goals, uncertainty of broad adoption of its approved products, if any, by physicians and consumers, and significant competition.</p>
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	197211	USD
CY2021Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	142766	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	153684	USD
CY2021Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	153684	USD
CY2021Q2	celc	Long Term Operating Lease Liability LongTermOperatingLeaseLiability	0	USD
CY2021Q2	us-gaap	Capital Leased Assets Gross CapitalLeasedAssetsGross	28932	USD
CY2021Q2	us-gaap	Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation	17841	USD
CY2021Q2	us-gaap	Capital Leases Balance Sheet Assets By Major Class Net CapitalLeasesBalanceSheetAssetsByMajorClassNet	11091	USD
CY2021Q2	celc	Finance Lease Liabilities FinanceLeaseLiabilities	11209	USD
CY2021Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	5830	USD
CY2021Q2	celc	Long Terms Portions LongTermsPortions	5379	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	97411	USD
CY2021Q2	us-gaap	Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	3627	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	64940	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	7255	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	0	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	3023	USD
CY2021Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	162351	USD
CY2021Q2	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	13905	USD
CY2021Q2	celc	Less Present Value Discount LessPresentValueDiscount	8667	USD
CY2021Q2	celc	Less Present Value Discounts LessPresentValueDiscounts	-78	USD
CY2021Q2	celc	Lessee Operating Lease Liability Amount Representing Services LesseeOperatingLeaseLiabilityAmountRepresentingServices	0	USD
CY2021Q2	celc	Less Amount Representing Services LessAmountRepresentingServices	2618	USD
CY2021Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	153684	USD
CY2021Q2	us-gaap	Finance Lease Liability FinanceLeaseLiability	11209	USD
	celc	Operating Lease Weighted Average Remaining Leases Term1 OperatingLeaseWeightedAverageRemainingLeasesTerm1	P0Y9M18D
	celc	Finance Lease Weighted Average Remaining Leases Term1 FinanceLeaseWeightedAverageRemainingLeasesTerm1	P1Y10M24D
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	43727	USD
	us-gaap	Operating Lease Cost OperatingLeaseCost	89157	USD
CY2021Q2	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	1447	USD
	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	2893	USD
CY2021Q2	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	21	USD
	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	45	USD
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	19869	USD
	us-gaap	Variable Lease Cost VariableLeaseCost	39738	USD
CY2021Q2	us-gaap	Lease Cost LeaseCost	65064	USD
	us-gaap	Lease Cost LeaseCost	131833	USD
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	66872	USD
	us-gaap	Operating Lease Payments OperatingLeasePayments	135446	USD
CY2021Q2	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	21	USD
	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	45	USD
CY2021Q2	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	1451	USD
	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	2900	USD
CY2021Q2	celc	Cash Paid For Operating And Finance Leases CashPaidForOperatingAndFinanceLeases	68344	USD
	celc	Cash Paid For Operating And Finance Leases CashPaidForOperatingAndFinanceLeases	138391	USD
CY2021Q1	celc	Issuance Of Common Stock Upon Closing Of Follow On Offering Net Shares IssuanceOfCommonStockUponClosingOfFollowOnOfferingNetShares	1971100	shares
CY2021Q1	celc	Issuance Of Common Stock Upon Closing Of Follow On Offering Including Shares Of Common Stock IssuanceOfCommonStockUponClosingOfFollowOnOfferingIncludingSharesOfCommonStock	257100	shares
CY2021Q1	celc	Public Offering Price PublicOfferingPrice	14.00
CY2021Q1	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	27600000	USD
CY2021Q1	us-gaap	Sales Commissions And Fees SalesCommissionsAndFees	1600000	USD
CY2021Q1	celc	Offering Expenses OfferingExpenses	200000	USD
CY2021Q2	celc	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Remainder Of Fiscal Year EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedRemainderOfFiscalYear	1247486	USD
CY2021Q2	celc	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Two Years EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinTwoYears	2034829	USD
CY2021Q2	celc	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Three Years EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinThreeYears	1476348	USD
CY2021Q2	celc	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Four Years EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFourYears	979053	USD
CY2021Q2	celc	Employee Service Share Based Compensation Non Vested Awards Compensation Cost Not Yet Recognized Within Five Years EmployeeServiceShareBasedCompensationNonVestedAwardsCompensationCostNotYetRecognizedWithinFiveYears	246916	USD
CY2021Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	5984632	USD
CY2021Q2	us-gaap	Share Based Compensation ShareBasedCompensation	540317	USD
CY2020Q2	us-gaap	Share Based Compensation ShareBasedCompensation	423193	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	989415	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	887842	USD
CY2021Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	14.40
CY2021Q2	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	500000	USD
CY2021Q2	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	15000000	USD
CY2021Q2	celc	Add Pik Interest Added To Principal AddPikInterestAddedToPrincipal	93397	USD
CY2021Q2	celc	Add Final Fee AddFinalFee	675000	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	466482	USD
CY2021Q2	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	1068847	USD
CY2021Q2	us-gaap	Long Term Notes Payable LongTermNotesPayable	14233068	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	5660024	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	7546698	USD
CY2021Q2	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	2561675	USD
CY2021Q2	us-gaap	Long Term Debt LongTermDebt	15768397	USD
	celc	Note8 License Agreement Disclosuretextblock Note8LicenseAgreementDisclosuretextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;"><strong>8. License Agreement</strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:left;">On April 8<sup>th</sup>, the Company entered into a license agreement with Pfizer to research, develop, manufacture and commercialize gedatolisib, a potent, well-tolerated, reversible dual inhibitor that targets PI3K and mTOR, for the treatment, diagnosis and prevention of all diseases. The Company paid Pfizer $5.0 million in upfront fees and issued to Pfizer $5.0 million of shares of the Company’s common stock pursuant to an Equity Grant Agreement. The upfront payment and the issuance of shares were expensed to research & development in full for the three months ending June 30, 2021. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Company is also required to make milestone payments to Pfizer upon achievement of certain development and commercial milestone events, up to an aggregate of $335.0 million. Additionally, the Company will pay Pfizer tiered royalties on sales of gedatolisib at percentages ranging from the low to mid-teens, which may be subject to deductions for expiration of valid claims, amounts due under third-party licenses and generic competition. Unless earlier terminated, the License Agreement will expire upon the expiration of all royalty obligations. The royalty period will expire on a country-by-country basis upon the later of (a) 12 years following the date of first commercial sale of such product in such country, (b) the expiration of all regulatory or data exclusivity in such country for such product or (c) the date upon which the manufacture, use, sale, offer for sale or importation of such product in such country would no longer infringe, but for the license granted in the License Agreement, a valid claim of a licensed patent right. </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:left;">The Company has the right to terminate the License Agreement for convenience upon 90 days’ prior written notice. Pfizer may not terminate the agreement for convenience. Either the Company or Pfizer may terminate the License Agreement if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either the Company or Pfizer may terminate the License Agreement in the event of specified insolvency events involving the other party.</p>
CY2021Q2	celc	Upfront Fees UpfrontFees	5000000.0	USD
CY2021Q2	celc	Common Stock Issued Value CommonStockIssuedValue	5000000.0	USD
CY2021Q2	celc	Milestone Payments MilestonePayments	335000000.0	USD

Files In Submission

Name	View Source	Status
0001654954-21-008769-index-headers.html	Edgar Link	pending
0001654954-21-008769-index.html	Edgar Link	pending
0001654954-21-008769.txt	Edgar Link	pending
0001654954-21-008769-xbrl.zip	Edgar Link	pending
celc-20210630.xsd	Edgar Link	pending
celc-20210630_cal.xml	Edgar Link	unprocessable
celc-20210630_def.xml	Edgar Link	unprocessable
celc-20210630_lab.xml	Edgar Link	unprocessable
celc-20210630_pre.xml	Edgar Link	unprocessable
celc_10q.htm	Edgar Link	pending
celc_10qimg1.jpg	Edgar Link	pending
celc_10qimg2.jpg	Edgar Link	pending
celc_10qimg3.jpg	Edgar Link	pending
celc_10qimg4.jpg	Edgar Link	pending
celc_10qimg5.jpg	Edgar Link	pending
celc_10q_htm.xml	Edgar Link	completed
celc_ex102.htm	Edgar Link	pending
celc_ex103.htm	Edgar Link	pending
celc_ex104.htm	Edgar Link	pending
celc_ex105.htm	Edgar Link	pending
celc_ex311.htm	Edgar Link	pending
celc_ex312.htm	Edgar Link	pending
celc_ex321.htm	Edgar Link	pending
celc_ex322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CELC
Celcuity Inc Stock $celc

2021 Q3 Form 10-Q Financial Statement

#000165495421008769 Filed on August 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC Celcuity Inc Stock $celc

2021 Q3 Form 10-Q Financial Statement

#000165495421008769 Filed on August 11, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CELC
Celcuity Inc Stock $celc